Tempus AI (NASDAQ:TEM) Shares Down 0% After Insider Selling

Tempus AI, Inc. (NASDAQ:TEM)’s share price fell 0% on Thursday following insider selling activity. The company traded as low as $47.12 and last traded at $48.02. 3,016,581 shares were traded during trading, a decline of 40% from the average session volume of 5,007,310 shares. The stock had previously closed at $48.03.

Specifically, Director David R. Epstein sold 990 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $46.83, for a total value of $46,361.70. Following the sale, the director now directly owns 26,284 shares of the company’s stock, valued at approximately $1,230,879.72. This represents a 3.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew Polovin sold 13,135 shares of Tempus AI stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total transaction of $603,947.30. Following the transaction, the executive vice president now directly owns 154,171 shares of the company’s stock, valued at approximately $7,088,782.58. This trade represents a 7.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In other news, CFO James William Rogers sold 23,030 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $45.97, for a total transaction of $1,058,689.10. Following the transaction, the chief financial officer now owns 164,750 shares in the company, valued at approximately $7,573,557.50. This trade represents a 12.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC boosted their target price on shares of Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. lowered shares of Tempus AI from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th. Bank of America lifted their price target on shares of Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Guggenheim reissued a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Finally, Loop Capital dropped their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $61.18.

Tempus AI Stock Down 0.0 %

The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The company’s 50 day moving average is $55.86 and its 200 day moving average is $51.48.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. First Horizon Advisors Inc. acquired a new position in Tempus AI in the 3rd quarter worth about $30,000. Operose Advisors LLC bought a new position in Tempus AI in the 4th quarter valued at approximately $25,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI during the 4th quarter worth approximately $34,000. Prestige Wealth Management Group LLC grew its holdings in Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after acquiring an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new position in shares of Tempus AI during the fourth quarter valued at $49,000. 24.22% of the stock is currently owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.